Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Luther A. Bartelt, Alena J. Markmann, Bridget Nelson, Jessica Keys, Heather Root, Heather Henderson, JoAnn Kuruc, Caroline Baker, D. Ryan Bhowmik, Yixuan J. Hou, Lakshmanane Premkumar, Caleb Cornaby, John L. Schmitz, Susan R. Weiss, Yara Park, Ralph S. Baric, Aravinda M. de Silva, Anne M. Lachiewicz, Sonia Napravnik, David van Duin, David M. Margolis
Abstract
In this study, in a high-risk population of patients admitted for COVID-19, we found an earlier time to hospital discharge among participants receiving CCP with nAb titers of >1:640 compared with participants receiving CCP with a lower nAb titer and no CCP-related AEs. The significance of our research is in identifying a dose response of CCP and clinical outcomes based on nAb titer.
Topics & Concepts
Convalescent plasmaCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicine2019-20 coronavirus outbreakCoronavirusAntibodyTiterBetacoronavirusNeutralizing antibodyImmunologyInternal medicineDiseaseInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19